Significance of regular somatostatin analogues and interferon-alfa application in patients with highly differentiated neuroendocrine tumors (clinical case)

Galina S. Emelianov; V. A Gorbunova; N. F Orel; A. A Markovich; A. E Kuzmiovn; V. Yu Selchuk

doi:10.17816/onco40104

Russian Journal of Oncology ›› 2014, Vol. 19 ›› Issue (6) : 30 -32. DOI: 10.17816/onco40104

Articles

research-article

Significance of regular somatostatin analogues and interferon-alfa application in patients with highly differentiated neuroendocrine tumors (clinical case)

Author information +

History +

PDF

Abstract

Presented clinical case demonstrates the importance of regular use of somatostatin analogues and interferon-alpha in patients with well differentiated NETs.

Keywords

neuroendocrine tumor / biochemical markers / somatostatin analogs

Cite this article

Download citation ▾

Galina S. Emelianov, V. A Gorbunova, N. F Orel, A. A Markovich, A. E Kuzmiovn, V. Yu Selchuk. Significance of regular somatostatin analogues and interferon-alfa application in patients with highly differentiated neuroendocrine tumors (clinical case). Russian Journal of Oncology, 2014, 19(6): 30-32 DOI:10.17816/onco40104

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Kaltsas G., Besser G., Grossman A. The Diagnosis and medical management of advanced neuroendocrine tumors. Endocrine Rev. 2004; 25(3): 458-511.

[2]	Funa К., Alm G.V., Ronnblom L., Oberg K. Evaluation of the natural killer cell-interferon system in patients with mid-gut carcinoid tumours treated with leucocyte interferon. Clin. Exp. Immunol. 1983; 53(3): 716-24.

[3]	Rosewicz, S. Detjen K., Scholz A., Marschall Z. Interferon-alpha: regulatory effects on cell cycle and angiogenesis. Neuroendocrinology. 2004; 80(1): 85-93.

[4]	Aparicio-Pages M.N., Verspaget H.W., Pena A.S., Jansen J.B., Lamers C.B. Natural killer cell activity in patients with neuroendocrine tumours of the gastrointestinal tract; relation with circulating gastrointestinal hormones. J. Neuropeptid. 1991; 20(1): 1-7.

[5]	Oberg K. Interferon in the management of neuroendocrine GEP tumors. Digest. 2000; 62 (Suppl. 1): 92-7.

[6]	Eriksson В., Oberg K. Interferon therapy of malignant endocrine pancreatic tumors. In: Endocrine Tumors of the Pancreas: Recent Advanced in Research and Management. 1995: 451-60.

[7]	Reisine T., Bell G. Molecular biology of somatostatin receptors. Endocr. Rev. 1995; 16: 427-42.

[8]	Susini C., Buscail L. Rationale for the use of somatostatin analogs as antitumor agents. Ann. Oncol. 2006; 17(12): 1733-42.

[9]	Kolby L., Persson G., Franzen S., Ahren B. Randomized clinical trial of the effect of interferon alpha on survival in patients with disseminated midgut carcinoid tumours. Br. J. Surg. 2003; 90(6): 687-93.

[10]

Faiss S., Pape U.F., Bohmig M., Dorffel Y., Mansmann U., Golder W. et al. Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors - the International Lanreotide and Interferon Alfa Study Group. J. Clin. Oncol. 2003; 21: 2689-96.

[11]	Arnold R., Rinke A., Klose K., Muller H., Wied M., Zamzow K. et al. Octreotide versus octreotide plus interferon-alpha in endocrine gastroenteropancreatic tumors: A randomized trial. Clin. Gastroenterol. Hepatol. 2005; 3: 761-71.